| Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF SJ Heidorn, C Milagre, S Whittaker, A Nourry, I Niculescu-Duvas, ... Cell 140 (2), 209-221, 2010 | 1682 | 2010 |
| The role of signaling pathways in the development and treatment of hepatocellular carcinoma S Whittaker, R Marais, AX Zhu Oncogene 29 (36), 4989-5005, 2010 | 1027 | 2010 |
| The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma EM Van Allen, N Wagle, A Sucker, DJ Treacy, CM Johannessen, ... Cancer discovery 4 (1), 94-109, 2014 | 985 | 2014 |
| A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition SR Whittaker, JP Theurillat, E Van Allen, N Wagle, J Hsiao, GS Cowley, ... Cancer discovery 3 (3), 350-362, 2013 | 448 | 2013 |
| Inhibitors of cyclin-dependent kinases as cancer therapeutics SR Whittaker, A Mallinger, P Workman, PA Clarke Pharmacology & therapeutics 173, 83-105, 2017 | 371 | 2017 |
| The Cyclin-dependent kinase inhibitor CYC202 (R-roscovitine) inhibits retinoblastoma protein phosphorylation, causes loss of Cyclin D1, and activates the mitogen-activated … SR Whittaker, MI Walton, MD Garrett, P Workman Cancer research 64 (1), 262-272, 2004 | 260 | 2004 |
| Paradox-breaking RAF inhibitors that also target SRC are effective in drug-resistant BRAF mutant melanoma MR Girotti, F Lopes, N Preece, D Niculescu-Duvaz, A Zambon, L Davies, ... Cancer cell 27 (1), 85-96, 2015 | 240 | 2015 |
| Gatekeeper mutations mediate resistance to BRAF-targeted therapies S Whittaker, R Kirk, R Hayward, A Zambon, A Viros, N Cantarino, ... Science translational medicine 2 (35), 35ra41-35ra41, 2010 | 184 | 2010 |
| In vitro and in vivo pharmacokinetic-pharmacodynamic relationships for the trisubstituted aminopurine cyclin-dependent kinase inhibitors olomoucine, bohemine and CYC202 FI Raynaud, SR Whittaker, PM Fischer, S McClue, MI Walton, SE Barrie, ... Clinical cancer research 11 (13), 4875-4887, 2005 | 160 | 2005 |
| The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma EM Allen, N Wagle, A Sucker, DJ Treacy, CM Johannessen, EM Goetz, ... Cancer Discov 4 (1), 94-109, 2014 | 110 | 2014 |
| The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. Cancer Discov. 2014; 4: 94–109. doi: 10.1158/2159-8290 EM Van Allen, N Wagle, A Sucker, DJ Treacy, CM Johannessen, ... CD-13-0617.[Europe PMC free article][Abstract][CrossRef][Academic Search], 0 | 108 | |
| Combined Pan-RAF and MEK inhibition overcomes multiple resistance mechanisms to selective RAF inhibitors SR Whittaker, GS Cowley, S Wagner, F Luo, DE Root, LA Garraway Molecular cancer therapeutics 14 (12), 2700-2711, 2015 | 88 | 2015 |
| The cyclin-dependent kinase inhibitor seliciclib (R-roscovitine; CYC202) decreases the expression of mitotic control genes and prevents entry into mitosis SR Whittaker, RH Te Poele, F Chan, S Linardopoulos, MI Walton, ... Cell Cycle 6 (24), 3114-3131, 2007 | 77 | 2007 |
| Novel potent BRAF inhibitors: toward 1 nM compounds through optimization of the central phenyl ring D Ménard, I Niculescu-Duvaz, HP Dijkstra, D Niculescu-Duvaz, ... Journal of medicinal chemistry 52 (13), 3881-3891, 2009 | 63 | 2009 |
| Dermatologic Cooperative Oncology Group of Germany (DeCOG) EM Van Allen, N Wagle, A Sucker, DJ Treacy, CM Johannessen, ... The genetic landscape of clinical resistance to RAF inhibition in metastatic …, 2014 | 61 | 2014 |
| Novel inhibitors of B-RAF based on a disubstituted pyrazine scaffold. Generation of a nanomolar lead I Niculescu-Duvaz, E Roman, SR Whittaker, F Friedlos, R Kirk, IJ Scanlon, ... Journal of medicinal chemistry 49 (1), 407-416, 2006 | 61 | 2006 |
| Pyridoimidazolones as novel potent inhibitors of v-Raf murine sarcoma viral oncogene homologue B1 (BRAF) D Niculescu-Duvaz, C Gaulon, HP Dijkstra, I Niculescu-Duvaz, A Zambon, ... Journal of medicinal chemistry 52 (8), 2255-2264, 2009 | 50 | 2009 |
| Novel hinge binder improves activity and pharmacokinetic properties of BRAF inhibitors A Zambon, D Ménard, BMJM Suijkerbuijk, I Niculescu-Duvaz, S Whittaker, ... Journal of medicinal chemistry 53 (15), 5639-5655, 2010 | 45 | 2010 |
| Potent BRAF kinase inhibitors based on 2, 4, 5-trisubstituted imidazole with naphthyl and benzothiophene 4-substituents D Niculescu-Duvaz, I Niculescu-Duvaz, BMJM Suijkerbuijk, D Ménard, ... Bioorganic & medicinal chemistry 21 (5), 1284-1304, 2013 | 44 | 2013 |
| Suppression of interferon gene expression overcomes resistance to MEK inhibition in KRAS-mutant colorectal cancer S Wagner, G Vlachogiannis, A De Haven Brandon, M Valenti, G Box, ... Oncogene 38 (10), 1717-1733, 2019 | 43 | 2019 |